Through expanding our knowledge of anelloviruses, our revolutionary platform can exploit unique properties and tissue tropisms to build vectors that can deliver diverse therapeutic modalities to a wide array of tissues.
The AnelloScope™ platform serves as the primary discovery engine driving our pipeline and platform growth through rapid mining of the natural Anellome for new targets for therapeutic design. The AnelloScope™ discovery engine consists of our Ring capture technology, optimized for circular anellovirus sequences, a high throughput data mining system, and proprietary computational pipeline to rapidly screen, identify, and characterize anellovirus diversity. We have identified many thousands of unique anellovirus sequences as a foundation for Ring’s rapidly growing database.
AnelloScreen™ technology can be used to rapidly characterize new anelloviruses discovered by the AnelloScope™ platform. Following identification, anelloviruses are screened for factors including tissue tropism, redosability, potency and immunogenicity. The results from the AnelloScreen™ process are fed back into the AnelloDesign™ computational pipeline to optimally combine hallmarks of each factor when designing AnelloVector™ and AnelloLP™ therapeutics.
Once anelloviruses are identified and screened, our computational pipeline combines genomic information to design a variety of AnellosVectors™ that harness the unique factors of anellovirus species to design therapies that are capable of targeting specific tissues, are able to be redosed, and retain potency without unwanted immunogenicity.
AnelloVector™ therapeutics are engineered viral particles that can be vectorized with varying flavors of nucleic acid, i.e, DNA or RNA. In addition for DNA, once administered, the nucleic acids will remain as episomes in the nucleus where they can be expressed without integrating onto chromosomal DNA. AnelloVector™ therapeutics have the rare potential to be harmless, transferring nucleic acids to new cells in a variety of tissue types without damaging tissues or activating the immune system. Ring has also unlocked a method that enables versatile payload capabilities and manufacturing modularity.
Ring’s in-house AnelloBricks™ manufacturing platform can produce therapies efficiently at scale in its in-house manufacturing facility. This allows the company to pursue clinical development of multiple AnelloVector™ drug products as well as establish and improve the scalable and modular process needed for full-scale commercial production.
Interested in partnering with us to build the future of programmable medicine?Reach out to us